消息面上，加科思近日宣布就其订立的增资协议及股权转让协议，已收到海松资本支付的1.25亿元的首 付款。该首付款的到账，进一步充盈了本集团的现金储备，也将为本集团后续创新肿瘤疗法管线研发的 推进提供助力。 据悉，加科思10月份公布，与海松资本及一名产业合作方签署增资及股权转让协议。根据本次协议，海 松资本将以人民币1.25亿元首付款及7500万元里程碑付款收购北京加科思旗下加科瑞康80%的股权。完 成后，北京加科思于加科瑞康持股将降至10%。公告称，该交易符合集团聚焦不同关键细胞通路的肿瘤 方向关键管线产品的战略发展。 智通财经APP获悉，加科思-B(01167)再涨超11%，截至发稿，涨10.28%，报8.69港元，成交额7382.33万 港元。 ...

Core Viewpoint - The announcement by 加科思-B (01167) regarding the capital increase and equity transfer agreement signifies a strategic move to enhance cash reserves and support the development of innovative cancer therapies [1] Group 1: Financial Transactions - The company’s subsidiary, 北京加科思, has received an initial payment of RMB 125 million from 海松资本 as part of the capital increase agreement [1] - This initial payment is expected to bolster the group's cash reserves, providing financial support for future research and development initiatives [1] Group 2: Strategic Implications - The agreements with 海松资本 and other partners are aimed at advancing the company's pipeline for innovative cancer therapies [1] - The successful execution of these agreements reflects the company's commitment to enhancing its operational capabilities and expanding its therapeutic offerings in the oncology sector [1]

Core Viewpoint - Edison Oncology Holding, a biotechnology company focused on developing targeted small molecule cancer therapies, has filed for an initial public offering (IPO) with plans to raise up to $25 million by offering 2.8 million shares at a price range of $8 to $10 per share [1] Company Overview - Edison Oncology is a clinical-stage biotechnology company dedicated to developing oncology small molecule candidates, with projects stemming from formulation improvements, repurposing existing drugs, and researching new mechanisms of action [1] - The company's product pipeline includes assets in 1-2a phase evaluations targeting ARID1A mutation cancers, replication stress pathways, ErbB-driven tumors, and pediatric solid tumors [1] Regulatory Pathways - The company is advancing its research through traditional and 505(b)(2) regulatory pathways, conducting early studies to assess safety, pharmacokinetics, and preliminary anti-tumor activity [1] Financials - For the 12 months ending September 30, 2025, the company reported revenue of $446,000 [1]